Déjà vu? MHRA reviews kava
This article was originally published in The Tan Sheet
Executive Summary
The Medicines & Healthcare products Regulatory Agency will conduct a formal 12-week "public consultation exercise" in January 2005 to assess "whether the controls on kava kava remain justified and proportionate" and to "review the evidence relating to the hepatotoxicity" of the herbal, the UK health agency announces Aug. 11. The ban on kava in unlicensed herbal medicines took effect in January 2003 following reports of liver damage associated with the ingredient's consumption (1"The Tan Sheet" Jan. 6, 2003, In Brief). Health ministers who prohibited kava's sale requested the two-year follow-up. MHRA will formally write to interest groups for comment in January...
You may also be interested in...
Kava banned in UK
Order prohibiting sale, supply, import of kava medicinal products will take effect in UK on January 13, Medicines Control Agency announces. Following examination of 70 reports of adverse liver reactions due to kava consumption - four cases resulting in death, seven in transplants - MCA "concluded that there is clear evidence linking kava...with rare cases of liver disease." However, agency notes it will review the ban in two years to assess whether it remains justified, and can review decision "at any time if new evidence emerges." The UK dietary supplement industry initially agreed to pull kava supplements from store shelves in December 2001 (1"The Tan Sheet" Dec. 24, 2001, p. 14)...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.